UCB Media released a press statement stating that UCB Pharma and Oxford University agreed today to collaborate on cutting-edge pharmaceutical research projects, enabling scientists from industry and academia to work together to develop innovative medicines to treat serious diseases in immunology and neurology.
The Oxford-UCB partnership will be funded by an amount of £3.6 million from UCB and will run over 3 years. A committee of UCB and Oxford University representatives will oversee the collaboration via regular meetings to look out for and monitor new projects. Between five and 10 projects will be selected for investigation over the course of the three-year agreement.
Professor Sir John Bell, Regius Professor of Medicine at Oxford University, said: “This is an exciting new partnership and I am eager to see the research that results. Partnerships between industry and academia will have an increasingly prominent role to play in the development of new drugs, therapies and medical technologies. Pooling expertise and resources is exactly what we should be doing to carry out the best research, identify the most promising new drug candidates and take them forward.